158 related articles for article (PubMed ID: 24434372)
1. Fluticasone furoate is more effective than mometasone furoate in restoring tobacco smoke inhibited SOCS-3 expression in airway epithelial cells.
Nasreen N; Gonzalves L; Peruvemba S; Mohammed KA
Int Immunopharmacol; 2014 Mar; 19(1):153-60. PubMed ID: 24434372
[TBL] [Abstract][Full Text] [Related]
2. Fluticasone propionate and Salmeterol combination induces SOCS-3 expression in airway epithelial cells.
Nasreen N; Khodayari N; Sukka-Ganesh B; Peruvemba S; Mohammed KA
Int Immunopharmacol; 2012 Jan; 12(1):217-25. PubMed ID: 22155101
[TBL] [Abstract][Full Text] [Related]
3. Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo.
Zhang N; Van Crombruggen K; Holtappels G; Lan F; Katotomichelakis M; Zhang L; Högger P; Bachert C
PLoS One; 2014; 9(4):e93754. PubMed ID: 24710117
[TBL] [Abstract][Full Text] [Related]
4. Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies.
Roumestan C; Henriquet C; Bousquet J; Mathieu M
Clin Exp Allergy; 2003 Jul; 33(7):895-901. PubMed ID: 12859444
[TBL] [Abstract][Full Text] [Related]
5. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo.
Baumann D; Bachert C; Högger P
Clin Exp Allergy; 2009 Oct; 39(10):1540-50. PubMed ID: 19538495
[TBL] [Abstract][Full Text] [Related]
6. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate.
Austin RJ; Maschera B; Walker A; Fairbairn L; Meldrum E; Farrow SN; Uings IJ
Eur Respir J; 2002 Dec; 20(6):1386-92. PubMed ID: 12503693
[TBL] [Abstract][Full Text] [Related]
7. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.
Crim C; Pierre LN; Daley-Yates PT
Clin Ther; 2001 Sep; 23(9):1339-54. PubMed ID: 11589253
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.
Atsuta J; Plitt J; Bochner BS; Schleimer RP
Am J Respir Cell Mol Biol; 1999 Apr; 20(4):643-50. PubMed ID: 10100995
[TBL] [Abstract][Full Text] [Related]
9. Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis.
Doulaptsi M; Wils T; Hellings PW; Martens K; Farré R; Vicario M; Fokkens W; Prokopakis E; Steelant B
World Allergy Organ J; 2021 Sep; 14(9):100585. PubMed ID: 34567350
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.
Salter M; Biggadike K; Matthews JL; West MR; Haase MV; Farrow SN; Uings IJ; Gray DW
Am J Physiol Lung Cell Mol Physiol; 2007 Sep; 293(3):L660-7. PubMed ID: 17575011
[TBL] [Abstract][Full Text] [Related]
11. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells.
Rossios C; To Y; To M; Ito M; Barnes PJ; Adcock IM; Johnson M; Ito K
Eur J Pharmacol; 2011 Nov; 670(1):244-51. PubMed ID: 21920359
[TBL] [Abstract][Full Text] [Related]
12. Effect of mometasone furoate by topical application on allergic rhinitis model in rats.
Sugimoto Y; Ishizawa K; Saitou K; Suzuki G; Tarumi T; Nakahara H; Kirino Y; Kamei C
Pharmacology; 2000 Aug; 61(2):91-5. PubMed ID: 10940782
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice.
Chapman RW; Sehring SJ; Garlisi CG; Falcone A; Kung TT; Stelts D; Minnicozzi M; Jones H; Umland S; Egan RW; Kreutner W
Arzneimittelforschung; 1998 Apr; 48(4):384-91. PubMed ID: 9608881
[TBL] [Abstract][Full Text] [Related]
14. Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro.
Wach F; Bosserhoff A; Kurzidym U; Nowok K; Landthaler M; Hein R
Skin Pharmacol Appl Skin Physiol; 1998; 11(1):43-51. PubMed ID: 9603668
[TBL] [Abstract][Full Text] [Related]
15. Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis.
Ortiz-Muñoz G; Martin-Ventura JL; Hernandez-Vargas P; Mallavia B; Lopez-Parra V; Lopez-Franco O; Muñoz-Garcia B; Fernandez-Vizarra P; Ortega L; Egido J; Gomez-Guerrero C
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):525-31. PubMed ID: 19164812
[TBL] [Abstract][Full Text] [Related]
16. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.
Mandl M; Nolop K; Lutsky BN
Ann Allergy Asthma Immunol; 1997 Sep; 79(3):237-45. PubMed ID: 9305231
[TBL] [Abstract][Full Text] [Related]
17. Fluticasone furoate inhibits cytokine secretion from nasal epithelial cells and reduces eosinophil survival in an in vitro model of eosinophilic inflammation.
Mullol J; Pujols L; Alobid I; Pérez-Gonzalez M; Fuentes M; de Borja Callejas F; Valero A; Picado C; Roca-Ferrer J
Int Arch Allergy Immunol; 2014; 163(3):225-33. PubMed ID: 24603043
[TBL] [Abstract][Full Text] [Related]
18. Cytokine inhibition by a novel steroid, mometasone furoate.
Barton BE; Jakway JP; Smith SR; Siegel MI
Immunopharmacol Immunotoxicol; 1991; 13(3):251-61. PubMed ID: 1940049
[TBL] [Abstract][Full Text] [Related]
19. Deposition of intranasal glucocorticoids--preliminary study.
Rapiejko P; Sosnowski TR; Sova J; Jurkiewicz D
Otolaryngol Pol; 2015; 69(6):30-8. PubMed ID: 26860605
[TBL] [Abstract][Full Text] [Related]
20. Klotho expression is reduced in COPD airway epithelial cells: effects on inflammation and oxidant injury.
Gao W; Yuan C; Zhang J; Li L; Yu L; Wiegman CH; Barnes PJ; Adcock IM; Huang M; Yao X
Clin Sci (Lond); 2015 Dec; 129(12):1011-23. PubMed ID: 26201096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
